Agenus Announces New Responses for AGEN1181
February 09 2021 - 8:45AM
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an
extensive pipeline of checkpoint antibodies, cell therapies,
adjuvants, and vaccines designed to activate immune response to
cancers and infections, today announced additional confirmed
objective clinical responses from its Phase 1/2 trial of AGEN1181,
its next-generation anti-CTLA-4, as monotherapy and in combination
with Agenus’ anti-PD-1 balstilimab.
“These are very exciting results which demonstrate the potential
of AGEN1181 as an efficacious next-generation CTLA-4 antibody.
AGEN1181 is showing activity in difficult-to-treat tumors without
the neuroendocrine or significant liver toxicities commonly
observed with the currently-approved CTLA-4 antibody ipilimumab,”
said Dr. Steven O’Day, Chief Medical Officer at Agenus. “The
responses seen in patients with ovarian and MSS colorectal cancer
are particularly encouraging given the generally low activity seen
with immunotherapy in these indications.”
The Phase 1 dose escalation trial has had no reports of
complement-mediated toxicities. These are severe toxicities
associated with first-generation CTLA-4 antibodies. The trial has
also defined the optimal combination dose for AGEN1181 +/-
balstilimab.
Agenus also presented on the first-ever report of intratumoral
Treg depletion with a CTLA-4 antibody in clinical trials at SITC
2020.
The summary of responses with AGEN1181 alone or in combination
with balstilimab are as follows:1
- CR in PD-L1(-)
MSS endometrial cancer patient (1181 monotherapy)
- CR by PET in
PD-L1(-) MSS endometrial cancer patient (1181 + bal)
- PR in PD-L1(-)
refractory ovarian cancer patient (1181 + bal)
- PR in colorectal
cancer patient (1181 + bal)
- PR in MSS
colorectal cancer patient (1181 + bal) – new confirmed
response
- PR in ovarian
cancer patient (1181 + bal) – new confirmed response
AGEN1181 alone and in combination with balstilimab has expanded
dosing into colorectal cancer. Phase 2 trials in additional cancer
indications are scheduled to commence shortly.
About AgenusAgenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. The
Company's vision is to expand the patient populations benefiting
from cancer immunotherapy by pursuing combination approaches that
leverage a broad repertoire of antibody therapeutics, adoptive cell
therapies (through its AgenTus Therapeutics subsidiary), and
proprietary cancer vaccine platforms. The Company is equipped with
a suite of antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support clinical
programs. Agenus is headquartered in Lexington, MA. For more
information, please visit www.agenusbio.com and our Twitter handle
@agenus_bio. Information that may be important to investors will be
routinely posted on our website and Twitter.
Forward-Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements regarding the therapeutic potential of AGEN1181 as an
efficacious next-generation CTLA-4 antibody and the planned
initiation of Phase 2 trials in additional cancer indications.
These forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially.
These risks and uncertainties include, among others, the factors
described under the Risk Factors section of our most recent
Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed
with the Securities and Exchange Commission. Agenus cautions
investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this press release, and Agenus undertakes no
obligation to update or revise the statements, other than to the
extent required by law. All forward-looking statements are
expressly qualified in their entirety by this cautionary
statement.
Contact:Agenus
Inc. Caroline
Bafundo 212-994-8209Caroline.Bafundo@agenusbio.com
_________________1 Response evaluation criteria in solid tumors
(RECIST v1.1)
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024